ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck injects new jobs in North Carolina

by Marc S. Reisch
August 2, 2019 | APPEARED IN VOLUME 97, ISSUE 31

Merck & Co. plans to spend $650 million on a 21,000 m2 vaccines plant in Durham, North Carolina, to satisfy growing demand for the recombinant human papillomavirus vaccines Gardasil and Gardasil 9. The expansion won’t come without some pain: Merck first plans to end bulk production of a chicken pox vaccine and eliminate 150 jobs at the site. Once the Gardasil unit comes on line, employment there will reach 1,600, about 400 more than at present.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment